News Focus
News Focus
Followers 24
Posts 4120
Boards Moderated 0
Alias Born 12/18/2019

Re: Roman516 post# 801828

Tuesday, 12/09/2025 11:20:05 PM

Tuesday, December 09, 2025 11:20:05 PM

Post# of 818484
NWBO didn't file with the FDA -- no company would pass on filing in the U.S. unless FDA told them they didn't have sufficient clinical evidence. NWBO has very limited revenue potential in a small personalized oncology market like the UK. A winning personalized oncology treatment, Gilead's Yescarta CAR-T, only had 318 patients paid for by NICE's CDF Charity in three years!!! All at very discounted pricing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News